EMEA-002582-PIP01-19-M01

Key facts

Active substance
Remibrutinib
Therapeutic area
Dermatology
Decision number
P/0170/2022
PIP number
EMEA-002582-PIP01-19-M01
Pharmaceutical form(s)
  • Age-appropriate oral solid dosage form
  • Coated tablet
Condition(s) / indication(s)
Treatment of chronic spontaneous urticaria
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating